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PRINCIPAL INVESTIGATOR O. PROGRAM DIRECTOR (last. first, Initial) 
James C. Powers 
NAME OF ORGANIZATION 
Georgia Institute of Technology 
PERIOD COVERED BY TH!S REPORT 
FROM 	 THROUGH 
June 1, 1974 	July 1, 1975 
TITLE (Repeat title shohn in Item 1 en first pa&e) 
X-RAY STUDIES OF ENZYME AND SMALL MOLECULE INTERACTIONS 
1. List publications: (a) published and not previously reported; (5) in press. Provide five reprints if not previously submitted. 
2. List all additions and deletions in professional personnel and any changes in effort. 
3. Progress Report. (See Instructions) 
.1a. Publications not previously reported. 
"Active-Site Specific Inhibitors of Elastase," James C. Powers and Peter M. Tuhy, 
Biochemistry, 12, 4767 (1973). 
"Inhibition of Chymotrypsin A with N-acyl and N-Peptidyl-2-phenylethylamines. 
Subsite Binding Free Energies," James C. Powers, B. Lee Baker, J. Brown andB . K. Chelm, 
J. Am. Chem. Soc., 96, 238 (1974). 
"Synthetic Active Site-Directed Inhibitors of Elastolytic Proteases," James C. Powers, 
D. L. Carroll and P. M. Tuhy, Ann. N.Y. Acad. Sci., 256, 420 (1975). 
lb. Publications in Press  
"Modification of Chymotrypsin with the Cyanate Reagent Ac-Phe(OCN)-OEt", James C. 
Powers, P. M. Tuhy and F. Witter, Submitted to Biochemistry. 
"Reactions of Acyl Carbazates with Proteolytic Enzymes," James C. Powers and D. L. 
Carroll, Submitted to J. Am. Chem. Soc. 
2. Professional Personnel Changes 
Norikazu Nishino - Postdoctorial Fellow-added 
David L. Carroll - Graduate Research Assistant - deletion (took job at Colgate 
Palmolive) 
Ronald Whitley - Graduate Research Assistant - deletion at end of summer (writing 
Ph.D.-thesis). 
3. Progress Report and Research Goals 
The object of this research is to study the interaction of small molecules such as 
inhibitors or virtual substrates with enzymes in order to provide information about 
binding modes, recognition sites and the mechanism of enzymatic catalysis. One goal is 
to obtain difference Fourier electron density maps of enzyme-small molecular complexes 
to elucidate the structural details of the interactions. A second goal is to correlate 
the reactivity of enzymes with substrates and inhibitors in solution with the structure 
of the crystalline enzyme as observed by x-ray crystallography. 
Peptide Carbazates. One goal set for the current year was to obtain a difference 
electron density map of chymotrypsin A
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The carbazyl enzyme is simply an acyl enzyme in which the alpha carbon atom has 
been replaced by a nitrogen atom. A structural study of this analog of the acyl 
enzyme intermediate in hydrolysis of peptide by serine proteases such as chymo-
trypsin, was expected to yield information on the mechanism of enzymatic peptide 
bond hydrolysis. Dave Carroll collected x-ray data on the carbazyl enzyme and 













James C. Powers 
site 
density were in the activetregion in line with our expectations. At this point, 
Dave left Georgia Tech to take a job and we have done no work on this derivative 
since that time. A summary of our work on the solution reactivity of carbazates 
is contained in the attached manuscript "Reaction of Acyl Carbazates with Proteo-
lytic Enzymes" which has been submitted to J. Am. Chem. Soc. Reprints not yet received. 
At present, it appears that obtaining a high resolution electron density map of 
the carbaztyl derivative of chymotrypsin will be difficult for two reasons. First, 
the derivative appears not to be strictly isomorphous and so considerable crystallo-
graphic refinement will be required. Secondly, I have been unable to convince another 
graduate student to undertake this problem. 
Recently, I have begun some collaborative studies with Greg Petsko (Wayne State 
Univ.) with the serine. protease Subtilisin Carlsberg. One goal for the next year is 
to study the stability of carbazyl derivatives of subtilisin Carlsberg to ascertain 
if a crystallographic study is feasible with this enzyme. 
Protease Subsite Specificity. We are just completing a computer analysis of 
the amino acid sequence around cleavage sites of polypeptide substrates byproteolytic 
enzymes. The source of our information was all papers which sequenced proteins or 
peptides which appeared in the literature over a 5 year period. We were able to 
obtain statistically significant information for three proteases (chymotrypsin, 
pepsin and thermolysin) and some data for other proteases such as elastase. The 
data is too extensive to discuss in a short space, so I will concentrate only on 
elastase. Elastase, un basis of a large number of papers in the literature, is 
thought to prefer primarily alanine as the P 1 residue in a substrate or inhibitor. 
In contrast, our data showed a high preference for valine or isoteucine. To follow 
up this result, we synthesized the inhibitors Ac-Ala-Ala-Pro-Va1CH2
C1 to compare 
with our best elastase inhibitor Ac-Ala-Ala-Pro•AlaCH2
C1. With porcine pancreatic 
elastase, both the valine and isoleucins chloromethyl ketone inhibitors were as 
effective or slightly more effective than our standard inhibitor Ac-Ala-Ala-Pro- 
AlaCH2C1. 
The inhibition of human leukocyte elastase, the enzyme probably responsible 
for emphysema and some inflammatory diseases, by these same chloromethyl ketones 
was then studied. To our great surprise, Ac-Ala-Ala-Pro-leeCH IC1 was 47 times 
more effective! I believe this is an important result since it is leading us 
closer to a treatment for this important disease. 
Our goals in this area for the future are primarily concerned with analyzing 
the data and preparing it for publication. 
Peptide Aloehvdes. Peptide aldehydes can be considered to be virtual substrates 
of serine proteases due to their close resemblance to nature substrates. It is 
likely that they are transition state analogs due to the similarity of the hemiacetal, 
which is probably 
.ENZ 	 ENZ 
1 
CH OH 2 	
CH
2 
0 	 hemiacetal 
1 
- C - H 	 R - C - H 
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0 	 OH 
formed as the aldehyde complexes with the enzyme, to the tetrahedral transition state 
involved in normal peptide bond hydrolysis. Our goal is to obtain a difference electron 
density map of a chymotrypsin - peptide alaehyde complex to elucidate the structure of 
this important intermediate in the catalytic mechanism. 
We have suceeded in synthesizing several peptide aldehydes including Z-PheH and 
'Vage -3- 
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AcAla-PheH (Phell = N1E!CH(CH2 C6 H5 
 )CHO) which are competitive inhibitors of chymotrypsin. 
.  
Crystals of chymotrypsin Ay into which the aldehydes have diffused, are isomorphons 
With native enzyme. We have this far taken zero level x-ray phOtographS of the
Complexes. 
Our immediate goal is to collect enough data on one or both of these complexes 
to allow calculation of a low resolution electron density map. 
If one of the derivatives seems suitable, we will then try to calculate a high 
resolution electron density map. In addition, we will probably shortly begin a 
similar x-ray crystallographic study using subtilisin Carlsbery in collaboration with 
Greg Petsko (Wayne State Univ.). 
-Acid Proteases. David Davies (NIH) is working on the crystal structure of an 
acid protease from Rhizopus Chinensis. The enzyme, related to pepsin, will probably 
be the first acid protease to be solved to atomic resolution. The goal of our initial 
research is to synthesize heavy atom derivatives which might be useful in the x-ray 
structure determination of this enzyme. 








-PheCHN 	We are currently studying the kinetics of tMeYr 
reaction with the Rhizopus Cfiinensis acid protease and pepsin. We will then supply 
these compounds to David Davies for crystallographic studies. 
Our future studies in this area will be determined by the initial crystallographic 
. results. If no further heavy atom derivatives are required, then we will begin the 
synthesis of virtual substrates for this enzyme. 
3. Significance 
From a study of the difference Fourier maps of small molecule-protein complexes, 
wevexpect to learn significant structural information about binding modes and recogni-
tion sites.of serine and acid proteases. It is already evident that we are able to 
synthesize some highly reactive inhibitors for chymotrypsin, subtilisin and elastase 
using crystallographic results. Our results with chymotrypsin and subtilisin also 
show that it is possible to build selectivity into an inhibitor, even when dealing 
with closely related enzymes. Indeed, it should be possible to design an inhibitor 
which is not only enzyme specific, but is species specific.• Thus we are approaching 
the day when we can design a drug to inhibit an enzyme system in only one particular 
type of all or one type of organismto the exclusion of all others. 
Practical application of our elastase inhibitors is much closer to fruition. 
Pulmonary emphysema is currently thought to result from the uninhibited proteolysis 
of lung tissue by elastase and related neutral proteases derived from leukocytes, 
macrophages or other cellular sources. Synthetic inhibitors capable of specifically 
inhibiting elastase would be expected to be useful reagents both for the treatment 
of emphysema and for the study of the biological function of elastolytic enzymes. 
The peptide chloromethyl ketone inhibitors 'of elastase, developed during early 
years of this grant, have been in much demand by other investigators for these 
purposes. The heart and Lung institute funded a 11/2 year contract to synthesize 
large quantities of these inhibitors and at present over two dozen investigators 
are utilizing these compounds in their own research. Thus, there is good reason 
to believe that these elastase inhibitors or related compounds will eventually 
find use, in the treatment of pulmonary disease. 
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as submitted last year. This was half-way through the 2 year budget period of GM-
8292-04. Therefore, this progress report covers the period since July 1, 1975 while 
-he manpower and budget figures cover the whole period beginning June 1, 1974. 
la. Publications not_  previously reported 
"Inhibition of Human Leukocyte Elastase by Peptide Chioromethyl Ketones", 
P. M. Tuhy and J. C. Powers, FEBS LETTERS, 50, 359 (1975). 
"Reaction of Acyl Carbazates with Proteolytic Enzymes", J. C. Powers 
and D. L. Carroll, Biochem. Biophys. Res. Comm., 67, 639 (1975) 
lb. Publications in Press 
"Modification of Chymotrypsin with the Cyanate Reagent Ac-Phe(OCN)-OEt", 
James C. Powers, P. M. Tuhy, and F. Witter, Submitted to Biochem. Piophy. Acta. 
2. Professional Personnel changes 
Chin Min Ham - Half Time Postdoctoral Fellow - added 
Frank Gupton - Graduate Research Assistant - added 
During the last grant period, I utilized some of the personnel money to support 
four graduate research assistants for short periods of Lime (usually the summer 
quarter). Their names and the length of support are listed on the manpower report. 
Change of Effort. During the last year, T have made the decision not to pursue 
protein crystallographic studies at Georgia Tech., but to pursue our research goals 
in collaboration with other protein crystallography groups. I will emphasize the 
'ynthetic and enzymatic aspects of the problems in my laboratory. There are two 
factors responsible for the decision. First, it is highly likely that the protease 
. nhibitors which we have been synthesizing for crystallographic studies will be 
useful in the treatment of diseases such as emphysema and I thus decided to concen-
trate on this aspect of the problem. And secondly, I came to the realization. that 
protein crystallographic studies could be more efficiently carried out in collabora-
tion with full-time practicing crystallographers. I am at presently actively 
collaborating with two crystallographers, David Davies at the NIH and Greg Petsko 
at Wayne State University. 
3. Progress Report  and Research Goals. The object of this research is to study the 
interaction of small molecules such as inhibitors or virtual substrates with enzymes 
in order to provide information about binding modes, recognition sites and the 
mechanism of enzymatic catalysis. One goal is to correlate the reactivity of 
enzymes with substrates and inhibitors in solution with the structure of the crystal-
line enzyme as observed by x-ray crystallography. This has allowed us to design 
and synthesize more effective enzyme inhibitors. 
Aza-Amino Acid Derivatives (Peptide Carbazates). Aza-amino acids are simply 
amino acid derivatives in which the a-carbon atom has been replaced by a nitrogen 
atom. 
N112-CH-CO2H 	 Nu 2-14—c0 2 11 
R 	 R 
amino acid 	 aza-amino acid 
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I will use a nomenclature for aza amino acid residues which is based on the 
nomenclature for the corresponding amino acid. Thus, I will refer to aza 
phenylalanine (-NHN(CH2C6H5)CO-) as Aphe, aza alanine (-NHN(CH3)CO-) as Aala 
and so forth. 
We have found peptides with aza-amino acid residues to be good inhibitors 
of serine proteases. For example, Ac-Ala-Aphe-ONp specifically acylates 











+ p-nitrophenol (HONp) 
With porcine pancreatic elastase, the acylated enzyme deacylates slowly and has 
a reasonable lifetime. Thus, the reagent Ac-Ala-Ala-Aala-ONp can be used as an 
effective inhibitor and as an active site titrant for elastase. 
Two enzymes have been implicated in tissue damage in pulmonary emphysema: 
human neutrophil leukocyte elastase and cathepsin G (a chymotrypsin-like enzyme). 
In the past year we have synthesized a number of peptide aza-amino acid deriva-
tives and have studied their reactivity toward the Hnt, elastase. The compounds 
are of the type Ac-Ala-Ala-Aaa-ONp where Ana= Aala,Aleu,Aval,Aile,Anval,Agly, 
Anleu. We have measured rates of acylation and deacylation for the reaction of 
these compounds with both porcine pancreatic elastase and HNL elastase. The 
norvaline compound Ac-Ala-Ala-Anval-ONp appears to be the most effective inhibitor 
for the HNL elastase. It acetylates the enzyme instantaneously and the half-life 
for the deacylation reaction is en. 12 hrs. This makes this compound a very 
effective inhibitor, although not irreversible like some of the chloromethyl 
ketones (Ac-Ala-Ala-Pro-ValCH2C1) which we prepared earlier. 
We have recently obtained a sample of cathepsin G, but have not yet had 
an opportunity to carry out any studies with that enzyme. One of our goals for 
the next year is to investigate the reactivity of this enzyme with carbazates 
such as Ac-Ala-Aphe-ONp and Ac-Ala-Ala-Aleu-ONp. 
Another of our goals for next year is to synthesize carbazates such as 
Ac-Ala-Aarg-ONp and investigate their reactivity toward trypsin-like enzymes. 
Many of the important enzymes involved in physiological processes like clotting 
and fertilization are trypsin like enzymes with specificity toward argimine 
residues. Thus, I feel it is worthwhile to investigate carbazates which react 
specifically with these enzymes in order to develop drugs which could he used 
to control or mediate the action of many of these proteases. 
Acid  Proteases. David Davies(NIH) is working on the crystal structure of 
an acid protease from Rhizonus Chinensis. The enzyme, related to pepsin, will 
probably be the first acid protease to be solved to atomic resolution. The 
goal of our initial research was to synthesize heavy atom derivatives which 
would he useful in the x-ray structure determination of this enzyme. 
We synthesized two useful inhibitors: CH3C01 4 802-PheCHN2 and IC6H4S02-PheCHN2 
and measured the kinetics of their reaction with both pepsin and the Rhizopus 
protease. We sent samples of these compounds to David Davies who has done 
preliminary crystallographic studies with the iodo compound. In addition, we 
have given the iodo compound to Sine Laursen in Denmark for use in the structure 
determination of the acid protease chvmosin. 
In a continuation of this research, we are engaged in the synthesis of 
virtual substrates of acid protease for use in both kinetic and crystallographic 
studies. The synthesis of Ac-Phe-Aphe-ONp, an analog of the pepsin substrate 
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by the enzyme and to be a decent competitive inhibitor. We have not yet had the 
opportunity to carry out kinetic studies. 
Our goals for the next year include the synthesis of other acid protease 
inhibitors such as Ac-Aphe-Phe-OEt and Ac-Aphe-Aphe-OEt and investigation of 
the kinetics of their reaction with pepsin and the Rhizopus Chinensis acid 
protease. 
Significance. It is evident that we have been able to design and synthesize 
some highly reactive inhibitors for serine proteases using information about binding 
modes and recognition sites gained from x-ray crystallography and solution kinetics. 
Indeed,.it now seems possible to design inhibitors which are not only enzyme 
specific, but are species specific. Thus, we are nearing the day when we can 
design a drug to inhibit an enzyme system in only one particular type of organism 
to the exclusion of all others. 
Practical application of the elastase inhibitors which we synthesized earlier 
under this grant is in more advanced stage. Pulmonary emphysema is thought to 
result from the proteolysis of lung tissue by elastase and possibly cathepsin G 
derived from leukocytes. Several investigators have now begun to study the effect 
of peptide chloromathyl ketones such as Ac-Ala-Ala-Pro-AlaCH2C1 and Ac-Ala-Ala-
Pro-Va1CH2C1 on emphysema in animal models. In addition, I have now sent 
Ac-Ala-Ala-Aala-ONp to over 10 other investigators for studies involving En 
elastase. Thus, there is good reason to believe that these elastase inhibitors 
or related compounds will eventually find use in the treatment of pulmonary disease. 
Invention Certification. 
Inventor - James C. Powers 
Title 	- Use of Aza-Amino Acid Derivatives for the Inhibition of Proteases 
and the Treatment of Emphysema, Arthritis and Related Diseases. 
The undersigned agrees to accept responsibility for the scientific and 
technical conduct of the project and for provision-of required progress reports 
if a grant is awarded as the result of this application. 
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Research Goals. The object of this research was to study the interaction 
of small molecules such as inhibitors or virtual substrates with enzymes 
in order to provide information about binding modes, recognition sites 
and the mechanism of enzymatic catalysis. One goal was to correlate the 
reactivity of enzymes with substrates and inhibitors in solution with the 
structure of the crystalline enzymes as observed by x-ray crystallography. 
Another goal was to use this information to design and synthesize more 
effective enzyme inhibitors. 
Summary of Progress. During the course of this research, our research 
emphasis shifted from crystallographic studies toward the design and synthesis 
of specific enzyme inhibitors. A number of reasons were responsible for 
this shift. First it appeared (and still appears) likely that the protease 
inhibitors which we were synthesizing for crystallographic studies will 
be useful in the treatment of diseases such as emphysema. I thus decided 
to concentrate on this aspect of the problem and am continuing with this 
research (supported by HL18679-Synthetic Protease Inhibitors). And secondly, 
I came to the realization that protein crystallographic studies could be 
more efficiently carried out in collaboration with full-time practicing 
crystallographers. At Georgia Tech I was never able to build up either 
enough interest in graduate students or enough equipment to seriously pursue 
protein crystallography. On the other hand we are actively collaborating 
with a number of protein crystallographers. We have sent inhibitors with 
heavy atoms to David Davies at NIH and Sine Laursen in Denmark for studies 
with acid proteases. We have sent chloromethyl ketones and aza-peptides 
to Greg Petako (Wayne State) for studies with subtilisin Carlsberg. And 
2 
more recently we have sent some metalloprotease inhibitors to Brian Matthews 
(Oregon) for studies with thermolysin. 
In the area of protease inhibitors, we have designed and synthesized 
some highly effective inhibitors for the granulocyte enzymes elastase and 
cathepsin G. Bath of these enzymes digest lung elastin and have been 
implicated in the pathogenesis of pulmonary emphysema. Chloromethyl ketone 
inhibitors which we developed early in the course of this research are now 
being tested by several investigators in animal models of emphysema. A 
more promising type of inhibitor is aza-peptides. These compounds have the 
potential for being more specific than chloromethyl ketones. Aza-peptides 
which inhibit both elastase and cathepsin G have been prepared and studied. 
At present we are investigating changes in the leaving group portion of 
aza-peptide structures. Up to now we have used a 27nitrophenol group due 
to the ease of studying the reactions with enzymes. The leaving group 
is however not suitable for in vivo studies. Several of the aza-peptides 
which we developed have found use as active site titrants of various serine 
proteases. 
The secondary specificity of the enzymes chymotrypsin, thermolysin, 
pepsin and papain have been investigated. In order to analyze the nature 
of the extended substrate binding site of these enzymes, we collected and 
analyzed the sites of proteolytic cleavage in a large number of proteins 
and polypeptides which were reported in the course of sequence determination. 
We were then able to determine the length of the extended binding region 
in each of these proteases, the preferences for individual amino acid residues 
at each subsite and the effect of terminal amino acid residues. 
3 
Detailed Progress Report. A number of neutral proteases have been 
isolated from human granulocytes. These include serine proteases such 
as elastase and cathepsin G. These proteases have attracted considerable 
interest recently since it is generally acknowledged that some or all of 
these enzymes are responsible for the tissue destruction that occurs in 
diseases such as emphysema. Since leukocytes are known to contain relative 
large amounts of elastase and due to its ability to attack elastic fibers, 
elastase is the prime candidate for the destructive agent. In addition 
purified human granulocyte elastase has been shown to induce experimental 
emphysema when instilled in dog lungs (Janoff et al, 1977). 
Both elastase and cathepsin G are serine proteases as shown by their 
characteristic reaction with diisopropylfluorophosphate (DFP). The action 
of both enzymes on the oxidized B chain of insulin has been studied (Blow, 
1977; Blow and Barrett, 1977). In addition kinetic studies with peptide 
2-nitroanilides have been reported (Zimmerman and Ashe, 1977). 
Natural plasma inhibitors such as a l-protease inhibitor (a l
-antitrypsin) ordinarily remove elastase or cathepsin G from the circulation 
whenever they are released from the granulocyte. Individuals lacking 
this inhibitor are predisposed toward emphysema. However, there are probably 
many other mechanisms for initiating of the disease since only a small 
percentage of emphysema patients are homozygotes in an a l-protease inhibitor 
deficiency. 
Chloromethyl Ketone Inhibitors. Peptide chloromethyl ketone inhibitors 
are a type of affinity label that have been extensively studied as inhibitors 
for serine proteases. A fairly detailed picture of the chloromethyl ketone 
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inhibition reaction has emerged from numerous chemical and crystallographic 
studies (Powers, 1977). 
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The rate at which a peptide chloromethyl ketone inhibits human granulocyte 
elastase is profoundly influenced both by its interaction with the primary 
substrate binding subsite (S 1, nomenclature of Schechter and Berger, 1967) 
of the enzyme and by its interaction at other subsites (Tuhy and Powers, 1975; 
Powers et al, 1977). A comparison of the effectiveness of individual 
peptide chloromethyl ketones can be made on the basis of their k obsd/[I] 
values, the equivalent of a second-order rate constant, where k obsd is the 
pseudo first-order rate constant for the inhibition reaction and [I] is 
the inhibitor concentration. Some representative kobsd/[I] 
 values at pH 
6.5 are listed in Table 1. The rates are approximately 1.4 to 4.4 times 
faster at pH 7.5. 
5 
Table 1. Inhibition of Human Granulocyte Elastase 







P1  effect 
Ac -Ala -Ala -Pro -ThrCH2Cl 0.15 
Ac -Ala -Ala -Pro -AlaCH2Cl 3.4 
Ac -Ala -Ala -Pro -IleCH
2Cl 133 
Ac -Ala -Ala -Pro -ValCH 2Cl 160 
Effect of the chain length 
Ac-Ala-Ala-AlaCH 2C1 0.28 
Ac -Ala-Ala -Ala -AlaCH 2Cl 0.97 
Ac-Ala-Pro-AlaCH
2C1 1.1 
Ac-Ala-Ala-Pro -AlaCH 2C1 4.4 










Ac -Ala-Ala -Pro -AlaCH 2Cl 4.4 
Ac-Ala -Pro -Ala -AlaCH
2
Cl 2.2 










pH 6.5, 0.1 M phosphate, 0.06 M NaCl, elastase lOpM, 30 ° , 5% (v/v) 
methanol. The rate of inhibition of elastase by Ac-Ala-Ala-Pro-AlaCH IC1 
was found to vary slightly when measured by different individuals on differ-
ent batches of enzyme. Both numbers are used in the above table to allow 
reporting of data for eachbgroup of compounds which was measured under 
identical circumstances. Suc ■ HOCOCH2CH2CO-. clie0-Sue ■ CH3OCOCH2CH2CO-. 
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A number of conclusions can be drawn concerning the extended substrate 
binding site of granulocyte elastase. The S
1 
subsite prefers Val>I1e>A1a> 
Thr. This is in contrast to porcine pancreatic elastase where the Val, Ile, 
and Ala inhibitors are all equally effective. This would indicate that the S 1 
 subsite is somewhat larger in granulocyte elastase. However, it will not 
accommodate a phenylalanine residue since Z-Gly-Leu-PheCH 2C1 will not inhibit 
the enzyme while Z-Gly-Leu-AlaCH 2C1 is a reasonable inhibitor. 
Studies with substrates show the same pattern with respect to the S 1 
 specificity. Granulocyte elastase cleaves the B chain of insulin at 5 
sites (2 major and 3 minor; Blow, 1977). Both of the major cleavages occur 
after a valine residue, while the minor cleavages occur after Cys(SO 3H), 
Ser and Ala. A similar trend is observed in the granulocyte elastase 




) values for the Val, Ile and Ala peptides were respectively 
27,000, 5400 and 3900. Thus a qualitative correlation is observed between 
chloromethyl ketone inhibition, 27nitroanilide hydrolysis and peptide bond 
cleavage. 
Extension of the peptide chain of a chloromethyl ketone inhibitor 
from a tripeptide to a tetrapeptide results in a 3 to 4 fold acceleration 
in the inhibition rate indicating that granulocyte elastase has an extended 
substrate binding site to interact with the inhibitor. The S 2 subsite of 
the enzyme prefers an amino acid residue with a long alkyl side chain. Chang-
ing the P 2 residue from an Ala to Pro in both the case of the tripeptide 
and tetrapeptide inhibitors results a 4 fold increase in the inhibiton rate. 
In addition, the P2 residue at both the major cleavage sites and one of 
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the minor cleavage sites of the oxidized insulin B chain is a leucine 
residue; the latter cleavage is not observed with porcine pancreatic elastase. 
In fact there is one other leucine residue in the B chain which is not at 
a cleavage site and that leucine is followed by a tyrosine residue (P 1) 
which probably prevents cleavage. Thus the evidence points to a strong 
secondary specificity for Pro or Leu at P 2 . 
The replacement of an alanyl residue at P 3 by a prolyl residue prevents 
inhibition in the case of tripeptides, but results in a small acceleration 
in the case of tetrapeptides. This is in contrast to porcine pancreatic 
elastase where this structural change prevents inhibition. 
Alterations in the P
5 
group have profound effects on the inhibition 
rate. The inhibitors Suc-Ala-Ala-Pro-Va1CH 2
C1 and Me0-Suc-Ala-Ala-Pro-
Va1CH2C1, which were synthesized to increase water solubility, are 7-8 
times more reactive than the acetyl compound at pH 7.5. Me0-Suc-Ala-Ala-
Pro -Va1CH2Cl 
is the best granulocyte elastase chloromethyl ketone inhibitor 
thus far reported. It would appear that the S5 subsite of granulocyte 
elastase contains some structural feature which interacts favorably with a 
succinyl or methyl succinyl grouping. This points out another significant 
difference between the granulocyte and porcine pancreatic enzymes, since the 
change from acetyl to succinyl or methyl succinyl has a relatively minor 
effect on the rate of inhibition of the porcine enzyme. 
The subsite specificity of human granulocyte elastase can be summarized 
as follows: P 1, Val>I1e>>A1a; P2 , Pro(=Leu?)>Phe>A1a; P3, Pro>Ala; P 5 , 
Me0-Suc->Suc->Ac-. 
Granulocyte Cathepsin G. Cathepsin G has been reported to be unreactive 
toward Tos-PheCH 2C1 but could be inhibited slowly by Z-PheCH2C1 and Z- 
8 
Gly-Gly-PheCH2C1 (Feinstein and Janoff, 1975). The effectiveness of more 
than a dozen chloromethyl ketone inhibitors of human cathepsin G were measured 
and are listed in Table 2 (Powers et al, 1977). The most effective inhibitor 
is Z-Gly-Leu-PheCH 2C1. Both the P1 Phe (ratio of kobsd/[I] for Z-Gly-Leu-
PheCH2C1/Z-Gly-Leu-AlaCH2C1 = 20) and the P2 Leu (ratio for Z-Gly-Leu-PheCH 2C1/ 
Z-Gly-Gly-PheCH 2C1 = 12.5) are important features of this inhibitor. The P 4 
 benzyloxycarbonyi (Z) group has an insignificant effect (Z-Gly-Gly-PheCH2C1/
Ac-Ala-Gly-PheCH 2C1 = 1). Except for Z-Gly-Leu-PheCH2C1, there is very little 
spread in the reactivities of the other inhibitors tested. 
Table 2. Inhibition of Human Granulocyte Cathepsin 










Ac-Ala-PheCH 2C1 3.5 
Z-Leu-PheCH 2C1 4.7 
Z-Gly-Gly-PheCH2C1 4.1 
Z-Gly-Leu-AlaCH 2C1 2.6 

















pH 7.5, 0.02 M phosphate, 1.0 M NaC1, cathepsin G 0.21pM, 30 °C, 
4.3X(v/v) methanol. 
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Cathepsin G cleavages of the oxidized insulin B chain occur at sites 
with a P
1 
Phe, Leu or Tyr (Blow and Barrett, 1977). With the k-nitroanilides 
Ac-Ala-Ala-Pro-X-27nitroanilides, only the X m Phe and Leu were cleaved, 
while those with Ala, Val and Ile were untouched (Zimmerman and Ashe, 1977). 
Thus a P
1 
Phe is a preferred resiude in the case of chloromethyl ketone 
inhibitors, peptide 2-nitroanilides and peptide substrates. However, in 
the case of chloromethyl ketone inhibitors subsite interactions can play a 
significant role. Z-Gly-Leu-AlaCH2C1 is a reasonable inhibitor even though 
the P
1 
residue is Ala. In addition, the change of a P
5 
acetyl to a methyl 
succinyl group in the case of Me0-Suc-Ala-Ala-Pro-Va1CH 2C1 prevents inhibition. 
This suggests that subsite interactions are effecting the catalytic site. 
Specificity of the Chloromethyl Ketone Inhibitors. The specificity 
of several chloromethyl ketone inhibitors of elastase and cathepsin G are 
outlined in Table 3. It is possible to selectively inhibit cathepsin G 
with Z-Gly-Leu-PheCH 2C1 and elastase with Me0-Suc-Ala-Ala-Pro-Va1CH 2C1. 
These inhibitors show no cross reactivity even after incubation for 2-4 
days at pH 7.5. Other inhibitors such as Ac-Ala-Ala-Pro-ValCH 2C1 are 
relatively effective at inhibiting both enzymes, but will not touch other 
serine proteases such as bovine pancreatic trypsin. 










elastase 	 0 




elastase 	 - 1560 
cathepsin G 	 0 
glutathione 0.88 





Under physiological conditions, chloromethyl ketones can react not 
only with serine proteases but with other nucleophilic groups. The alkylation 
of sulfhydryl groups could be a significant side reaction. In order to 
evaluate the significance of such side reactions, the rate of reaction of 
glutathione with Me0-Suc-Ala-Ala-Pro-ValCH
2Cl was measured and is listed 
in Table 3. The rate is quite slow and the inhibitor would descriminate 
in favor of leukocyte elastase over glutathione by a factor of 1770 if the 
concentrations were equivalent. Thus Me0-Sue-Ala-Ala-Pro-ValCH2C1 appears 
to be a highly reactive and selective inhibitor for use in physiological 
situations. However, it should be noted that cellular thiol proteases such 
as cathepsin B1 can also react with chloromethyl ketones and it remains 
to be seen whether an inhibitor can be constructed with would be able to 
descriminate between elastase and cellular thiol proteases. 
Aza-peptides. Aza-amino acid residues are analogs of amino acids 
in which the a-CB has been replaced by a nitrogen atom. This substitution 
has a profound effect on the reactivity of aza-peptides, i.e., those 
containing aza-amino acid residues. In particular, aza-peptide 27 
nitrophenyl esters are inhibitors and active site titrants of several 
serine proteases (Powers and Gupton, 1977). Inhibition of these enzymes 
is believed to arise from the acylation of the active site serine yielding 








Ser 	 Si 	Ser 
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The reaction of granulocyte elastase with a number of aza-peptide 27 
nitrophenyl esters has been studied and some of the results are listed 
in Table 4. Most of the aza-peptides acylate elastase rapidly, although 
the rates are variable. The reaction of many of aza-peptides such as 
Ac-ala-Ala-Anle-ONp with elastase are complete in less than 10 s. However, 
Ac-Ala-Aphe-ONp acylates elastase very slowly. The kinetics of the reaction 
are described in detail elsewhere (Powers and Gupton, 1977), but with most 
of the inhibitors, k
cat 
is equal to the deacylation (or reactivation) rate 
of the acylated enzyme. Aza-peptides with low k cat values are more suitable 
inhibitors since the acylated enzyme formed will regain enzyme activity 
more slowly. The best inhibitor in the series is Ac-Ala-Ala-Anle-ONp which 
acylates elastase in less than 10 s and has no measurable kcat at either 
pH 6.0 or pH 7.0. 
Ac-Ala -Ala -Aval -0Np 3500 
Ac -Ala -Ala -Aile -0Np 59 
Ac -Ala -Ala -Aala -0Np 20 
Ac -Ala -Ala -Anva -0Np 14 
Ac -Ala -Ala -Aleu -0Np <1.9 
Ac -Ala -Ala -Anle -0Np <1.9 









Table 4. Reaction of Granulocyte Elastase and Cithepsin G 







 elastase 	 cath psin G 
a
pH = 6.0, 0.1 M citrate. Aval = -NHN(CH(CH 3 ) 2)C0-; Aile = 





















The rates of Ac -Ala -Ala -Pro -X -2 .-nitroanilide hydrolysis (Zimmerman and 
Ashe, 1977) can be compared to the kcat values in Table 4. With the 27 
nitroanilides the order of reactivity was X=Val>Ile>Ala>Leu, while with 
aza-peptides the k
cat 
values followed the same pattern of Aval>Aile>Aala>Aleu. 
The confirms our expectation that aza-peptides are interacting with elastase 
in a manner similar to substrates. 
Cathepsin G was also inhibited by several aza-peptides (Table 4). 
Some specificity is observed since the Aile, Aala and Anva peptides will 
not react with cathepsin G, while Ac-Ala-Aphe-ONp reacts only very slowly 
with elastase. We believe it will be possible to increase the specificity 
of the aza-peptides by substituting other groups for the 27nitrophenyl 
leaving group. 
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Aza-peptide 2-nitrophenyl esters can also be used as active site 
titrants for granulocyte proteases. A "burst" of 2 .-nitrophenol is released 
in the reaction and under the proper conditions this is stoichiometric 
with the normality of active sites in the enzyme solution. In particular 
we have utilized Ac-Ala-Ala-Aala-ONp to titrate granuolcyte elastase and 
Ac-Ala-Ala-Anle-ONp to titrate cathepsin G. 
Significance and Prospectives. A number of different types of inhibitors 
for granulocyte proteases are now available and new inhibitor structures such 
as cis-unsaturated fatty acids (Ashe and Zimmerman, 1977) are being uncovered. 
Some of the inhibitors are quite specific. There is considerable potential 
for the use of synthetic elastase inhibitors for the treatment of emphysema. 
They have the advantage of being readily synthesizable and may be able to 
diffuse to cellular sites which are inaccessible to larger molecules. In 
addition there is the prospect of relatively direct application at the site 
of tissue destruction via aerosol. 
In the last 18 months we have shipped samples of our inhibitors to 
50 other investigators. Several of these investigators have begun studies 
with elastase inhibitors in animal models of emphysema. There is a good 
possibility that the course of disease could be arrested by the use of the 
appropriate inhibitor. Whether lung healing would also occur is an unanswered 
question. Protease inhibitors could also be used to prvent the occurrence 
of the disease in high risk groups such as smokers. At present an obvious and 
urgent need is for more animal testing to evaluate the therapeutic possibilities 
14 
of inhibitors of granulocyte proteases. Only in this way can the limitations 
of the currently available protease inhibitors be uncovered so that more 
ideal reagents will be available in the future. 
15 
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